Adeno-associated virus vectors are a powerful tool for gene transfer approaches. We have established a simple and fast plasmid-based production system for achieving high adeno-associated virus titers within 6 working days. The same procedure can be used for all serotypes and thus allows direct comparability of different serotypes. In this protocol we describe a step-by-step procedure that results in well-characterized vectors suitable for both in vitro approaches and preclinical studies.
Get full access to this article
View all access options for this article.
References
1.
CotmoreSF, Agbandje-McKennaM, ChioriniJA, et al.The family Parvoviridae. Arch Virol, 2014; 159:1239–1247.
2.
GrimmD, KernA, RittnerK, et al.Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther, 1998; 9:2745–2760.
3.
MatsushitaT, ElligerS, ElligerC, et al.Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther, 1998; 5:938–945.
4.
XiaoX, LiJ, SamulskiRJ, Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 1998; 72:2224–2232.
5.
SonntagF, KötherK, SchmidtK, et al.The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J Virol, 2011; 85:12686–12697.
6.
TratschinJD, WestMH, SandbankT, et al.A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol, 1984; 4:2072–2081.
7.
HermonatPL, MuzyczkaN, Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A, 1984; 81:6466–6470.
8.
GrimmD, KayMA, KleinschmidtJA, Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther, 2003; 7:839–850.
9.
BoothMJ, MistryA, LiX, Thrasher, et al.Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Ther, 2004; 11:829–837.
10.
ConwayJE, RhysCM, ZolotukhinI, et al.High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther, 1999; 6:986–993.
11.
HwangKK, MandellT, Kintner, et al.High titer recombinant adeno-associated virus production using replication deficient herpes simplex viruses type 1. Mol Ther, 2003; 7:S14–S15.
12.
KangW, WangL, HarrellH, et al.An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther, 2009; 16:229–239.
13.
ThomasDL, WangL, NiamkeJ, et al.Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum Gene Ther, 2009; 20:861–870.
14.
GriegerJC, SoltysSM, SamulskiRJ. Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol Ther, 2016; 24:287–297.
15.
NegreteA, KotinRM, Production of recombinant adeno-associated vectors using two bioreactor configurations at different scales. J Virol Methods, 2007; 145:155–161.
16.
NegreteA, YangLC, MendezAF, et al.Economized large-scale production of high yield of rAAV for gene therapy applications exploiting baculovirus expression system. J Gene Med, 2007; 9:938–948.
17.
NegreteA, EstebanG, KotinRM, Process optimization of large-scale production of recombinant adeno-associated vectors using dielectric spectroscopy. Appl Microbiol Biotechnol, 2007; 76:761–772.
18.
GaudetD, deWJ, TremblayK, et al.Review of the clinical development of alipogene tiparvovec genetherapy for lipoprotein lipase deficiency. Atheroscler Suppl, 2010; 11:55–60.
19.
FranssenR, GaudetD, StroesES, et al.AAV1-LPLS447X gene therapy with alipogenetiparvovecprevents pancreatitis in lipoprotein lipase deficiency. Circulation, 2009; 120:S591–S592.
20.
CarpentierA, FrischF, LabbeSM, et al.Gene therapy with alipogenetiparvovec results in enhancedpost-prandial clear ance of low density chylomicrons in LPLD patients. Circulation, 2010; 122(21 Suppl):A16900 [abstract].
21.
GaudetD, MethotJ, GagneC, et al.Modificationsin triglyceride-rich lipoprotein metabolism inducedby alipogenetiparvovec (AAV1-LPLS447X GeneTherapy) correlate with clinical benefit in patientswith lipoprotein lipase deficiency (LPLD). Circulation, 2010; 122(21 Suppl.):A21355 [abstract].
22.
FlotteTR, TrapnellBC, Humphries, et al.Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther, 2011; 22:1239–1247.
23.
WangXS, PonnazhaganS, SrivastavaA, Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions. J Virol, 1996; 70:1668–1677.
24.
LeuchsB, RoscherM, MüllerM, et al.Standardized large-scale H-1PV production process with efficient quality and quantity monitoring. J Virol Methods, 2016; 22948–22959.
25.
ReedSE, StaleyEM, MayginnesJP, et al.Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. J Virol Methods, 2006; 138:85–98.
26.
DubielzigR, KingJA, WegerS, et al.Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes. J Virol, 1999; 73:8989–8998.
27.
GaoGP, AlviraMR, WangL, et al.Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A, 2002; 99:11854–11859.
28.
MüllerOJ, LeuchsB, PlegerST, et al.Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res, 2006; 70:70–78.
29.
WangZ, MaHI, LiJ, et al.Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther, 2003; 10:2105–2111.
30.
RaptiK, Louis-JeuneV, KohlbrennerE, et al.Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther, 2012; 20:73–83.
31.
ZolotukhinS, ByrneBJ, MasonE, et al.Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther, 1999; 6:973–985.
32.
LockM, McGorrayS, Auricchio, et al.Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther, 2010; 21:1273–1285.
33.
HermensWT, ter BrakeO, Dijkhuizen, et al.Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum Gene Ther, 1999; 10:1885–1891.
